Human Skin Permeation Studies with PPARγ Agonist to Improve Its Permeability and Efficacy in Inflammatory Processes

Human Skin Permeation Studies with PPARγ Agonist to Improve Its Permeability and Efficacy in Inflammatory Processes

Rosacea is the most common inflammatory skin disease. It is characterized by erythema, inflammatory papules and pustules, visible blood vessels, and telangiectasia. The current treatment has limitations and unsatisfactory results. Pioglitazone (PGZ) is an agonist of peroxisome proliferator-activated...

Full description

Bibliographic Details
Main Authors:	Marcelle Silva-Abreu, Lupe Carolina Espinoza, María José Rodríguez-Lagunas, María-José Fábrega, Marta Espina, María Luisa García, Ana Cristina Calpena
Format:	Article
Language:	English
Published:	MDPI AG 2017-11-01
Series:	International Journal of Molecular Sciences
Subjects:	skin permeation PPAR-γ pioglitazone limonene rosacea inflammation
Online Access:	https://www.mdpi.com/1422-0067/18/12/2548

Similar Items

Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia
by: Ivan Ramirez-Moral, et al.
Published: (2021-08-01)

Comparative Study of Ex Vivo Transmucosal Permeation of Pioglitazone Nanoparticles for the Treatment of Alzheimer’s Disease
by: Marcelle Silva-Abreu, et al.
Published: (2018-03-01)

PPAR-γ agonist pioglitazone improves semen quality and testicular histomorphometrics with partial reversal of hyperglycaemia in alloxan-induced diabetic rats
by: O.B. Akinola, et al.
Published: (2015-12-01)

Sex-Based Selectivity of PPARγ Regulation in Th1, Th2, and Th17 Differentiation
by: Hong-Jai Park, et al.
Published: (2016-08-01)

NRF2 and PPAR-γ Pathways in Oligodendrocyte Progenitors: Focus on ROS Protection, Mitochondrial Biogenesis and Promotion of Cell Differentiation
by: Chiara De Nuccio, et al.
Published: (2020-09-01)

Pulmonary Hypertension in Obese Mice Is Accompanied by a Reduction in PPAR-γ Expression in Pulmonary Artery
by: Any Elisa de Souza Schmidt Gonçalves, et al.
Published: (2021-09-01)

Activated PPARγ Abrogates Misprocessing of Amyloid Precursor Protein, Tau Missorting and Synaptotoxicity
by: Susanne Moosecker, et al.
Published: (2019-06-01)

Corrigendum: Activated PPARγ Abrogates Misprocessing of Amyloid Precursor Protein, Tau Missorting and Synaptotoxicity
by: Susanne Moosecker, et al.
Published: (2020-11-01)

Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
by: Chi-Hung Liu, et al.
Published: (2020-01-01)

PPAR-γ Modulators as Current and Potential Cancer Treatments
by: Tiange Chi, et al.
Published: (2021-09-01)

Cytosolic and nuclear distribution of PPARγ2 in differentiating 3T3-L1 preadipocytes
by: Philippe Thuillier, et al.
Published: (1998-12-01)

PPARγ Agonists: Emergent Therapy in Endometriosis
by: Alexandre Vallée, et al.
Published: (2021-06-01)

Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease
by: Carmen Ciavarella, et al.
Published: (2020-04-01)

Pioglitazone-Mediated Peroxisome Proliferator-Activated Receptor γ Activation Aggravates Murine Immune-Mediated Hepatitis
by: Rike Schulte, et al.
Published: (2020-04-01)

Celecoxib inhibits acute edema and inflammatory biomarkers through peroxisome proliferator-activated receptor-γ in rats
by: Gholamreza Houshmand, et al.
Published: (2020-12-01)

Optimized Structure-based Methodology for Studying PPARγ Partial Agonists
by: Merilin Al Sharif, et al.
Published: (2018-03-01)

Pioglitazone Alleviates Cardiac Fibrosis and Inhibits Endothelial to Mesenchymal Transition Induced by Pressure Overload
by: Wen-Ying Wei, et al.
Published: (2017-12-01)

Effect of pioglitazone treatment in a patient with secondary multiple sclerosis
by: Pershadsingh Harrihar A, et al.
Published: (2004-04-01)

Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR-γ (Pro12Ala)
by: Fatemeh Namvaran, et al.
Published: (2013-01-01)

Enhancement of cognitive functions by rice bran extract in a neuroinflammatory mouse model via regulation of PPARγ
by: A.O. Mostafa, et al.
Published: (2018-09-01)

Ciglitazone—a human PPARγ agonist—disrupts dorsoventral patterning in zebrafish
by: Vanessa Cheng, et al.
Published: (2019-11-01)

Pioglitazone Reduces β Amyloid Levels via Inhibition of PPARγ Phosphorylation in a Neuronal Model of Alzheimer’s Disease
by: Qiankun Quan, et al.
Published: (2019-07-01)

PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ
by: Dong Hyun Kim, et al.
Published: (2020-12-01)

Potential of Natural Products in the Inhibition of Adipogenesis through Regulation of PPARγ Expression and/or Its Transcriptional Activity
by: Shi Feng, et al.
Published: (2016-09-01)

Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR-ɤ
by: Pingping Xia, et al.
Published: (2018-03-01)

PPARα and PPARγ as main regulators of fatty acid metabolism
by: Mirosław Kucharski, et al.
Published: (2018-10-01)

Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model
by: Amandeep Mahal, et al.
Published: (2018-07-01)

Selective Tissue Distribution Mediates Tissue-Dependent PPARγ Activation and Insulin Sensitization by INT131, a Selective PPARγ Modulator
by: Xinni Xie, et al.
Published: (2017-05-01)

PPARγ agonist use and recurrence of atrial fibrillation after successful electrical cardioversion
by: Jun Gu, MD, PhD, et al.
Published: (2017-09-01)

Molecular docking studies on potential PPAR-γ agonist from Rhizophora apiculata
by: Gurudeeban Selvaraj, et al.
Published: (2014-07-01)

Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model
by: Yuji Nakano, et al.
Published: (2020-07-01)

PPARγ and Cognitive Performance
by: Michele d’Angelo, et al.
Published: (2019-10-01)

Ellagic acid potentiates insulin sensitising activity of pioglitazone in L6 myotubes
by: Rakesh P. Nankar, et al.
Published: (2015-05-01)

DHA increases adiponectin expression more effectively than EPA at relative low concentrations by regulating PPARγ and its phosphorylation at Ser273 in 3T3-L1 adipocytes
by: Jia Song, et al.
Published: (2017-08-01)

PPARγ Modulates Long Chain Fatty Acid Processing in the Intestinal Epithelium
by: Kalina Duszka, et al.
Published: (2017-11-01)

Identification of an irreversible PPARγ antagonist with potent anticancer activity
by: Youyi Peng, et al.
Published: (2020-12-01)

Structural and Dynamic Elucidation of a Non-acid PPARγ Partial Agonist: SR1988
by: Rebecca L. Frkic, et al.
Published: (2018-09-01)

Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds
by: Lars Porskjær Christensen, et al.
Published: (2018-09-01)

Pioglitazone downregulates Twist-1 expression in the kidney and protects renal function of Zucker diabetic fatty rats
by: Zijian Wang, et al.
Published: (2019-10-01)

A proline-type fullerene derivative inhibits adipogenesis by preventing PPARγ activation
by: Megumi Funakoshi-Tago, et al.
Published: (2016-03-01)